Protocol summary
-
Study aim
-
To evaluate the effect of intraoperative low-dose ketamine on postoperative sleep quality using the Sleep Numerical Rating Scale on postoperative days 1and 3.
-
Design
-
A single-center, two-arm, parallel-group, randomized, double-blind, placebo-controlled clinical trial involving 120 participants (60 per group), with 1:1 allocation using a computer-generated randomization sequence.
-
Settings and conduct
-
The trial will be conducted at Taleghani Hospital in Tehran in adults undergoing elective major abdominal surgery. Participants will receive low-dose ketamine or placebo, with participants, care providers, outcome assessors, and the data analyst blinded to allocation.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Age 18–80 years.
ASA Physical Status I–III.
Elective major abdominal surgery
Provision of written informed consent
exclusion criteria:
Minor surgery
Severe hepatic or renal failure
Severe psychiatric disorder
History of Severe Sleep Disturbance.
Refusal to participate in the study.
-
Intervention groups
-
Ketamine Group: 0.25 mg/kg bolus, followed by a 0.1 mg/kg/h infusion until the end of surgery.
Placebo Group: Bolus and infusion of saline with the same volume.
-
Main outcome variables
-
Postoperative sleep quality on days 1–3, postoperative pain, need for rescue analgesia, and adverse effects, including dizziness, hallucinations, nightmares, and agitation.
General information
-
Reason for update
-
Because the number of eligible patients undergoing hepatobiliary surgery at Ayatollah Taleghani Hospital has decreased, and achieving the required sample size has become difficult, continuing to recruit exclusively from patients undergoing hepatobiliary surgery has become challenging. This reduction in patient referrals and surgical procedures, particularly in recent months, has significantly affected the recruitment process.
Therefore, we kindly request your consideration and approval to modify the study's target population from patients undergoing major hepatobiliary surgery to patients undergoing major abdominal surgery to facilitate recruitment of the required sample size.
The other major aspects of the study design, including the randomized, double-blind clinical trial design, the intervention under investigation, and the primary outcome, will remain unchanged. We will amend the protocol and other relevant study documents accordingly to reflect this modification.
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT20260711070122N1
Registration date:
2026-07-25, 1405/05/03
Registration timing:
prospective
Last update:
2026-08-31, 1405/06/09
Update count:
1
-
Registration date
-
2026-07-25, 1405/05/03
-
Registrant information
-
-
Recruitment status
-
recruiting
-
Funding source
-
-
Expected recruitment start date
-
2026-08-01, 1405/05/10
-
Expected recruitment end date
-
2027-07-31, 1406/05/09
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
The Effect of Low-Dose Ketamine on Sleep Quality During the Early Postoperative Days After Major Abdominal Surgery: A Randomized, Double-Blind Clinical Trial
-
Public title
-
The Effect of Ketamine on Sleep Quality After AbdominalSurgery
-
Purpose
-
Prevention
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
Age range: 18–80 years
Patients with ASA physical status I–III
Candidates for elective major abdominal surgery
Extubation at the end of surgery or within the first postoperative hours
Ability to comprehend and complete the sleep and pain questionnaires
Written informed consent
Exclusion criteria:
Minor surgery, such as uncomplicated cholecystectomy
Expected need for mechanical ventilation beyond the first postoperative night
Preoperative hepatic encephalopathy
Severe renal failure
Severe psychiatric illness, active psychosis, or hallucinations
Severe preoperative insomnia (Athens Insomnia Scale [AIS] score ≥ 6)
Chronic ketamine use
Substance abuse
Declining to participate in the study
-
Age
-
From 18 years old to 85 years old
-
Gender
-
Both
-
Phase
-
3
-
Groups that have been masked
-
- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser
-
Sample size
-
Target sample size:
120
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
Simple randomization: In this study, the unit of randomization will be the individual patient. After assessment of eligibility criteria and written informed consent, eligible patients will be allocated in a 1:1 ratio to either the ketamine or placebo group. Simple randomization will be used, and no stratified or cluster randomization will be performed.
Before participant recruitment begins, the random allocation sequence will be generated using computer-generated random numbers by an independent individual who will have no role in participant recruitment, intervention delivery, outcome assessment, or data analysis. According to this sequence, each participant enrolled consecutively will be assigned to one of two groups: ketamine or placebo.
To ensure allocation concealment, the master randomization list will be accessible only to the independent pharmacist or nurse responsible for preparing the study medication. The investigator responsible for assessing eligibility and enrolling participants will not have access to the allocation sequence. After eligibility has been confirmed and written informed consent obtained, the next sequential study number will be assigned to the participant, and the independent individual will prepare the study medication corresponding to that number.
Ketamine and placebo will be prepared in identical syringes or infusion pumps, with identical appearance, volume, and labeling. Participants, surgeons, anesthesiologists, intensive care unit nurses, outcome assessors, and the data analyst will remain unaware of treatment allocation until data collection and analysis are complete.
-
Blinding (investigator's opinion)
-
Double blinded
-
Blinding description
-
This is a randomized, double-blind, placebo-controlled clinical trial. Participants, healthcare providers, outcome assessors, and the data analyst will be blinded to group allocation. Patients will be randomly assigned in a 1:1 ratio to ketamine or placebo using a computer-generated sequence. The study drugs will be prepared by an independent pharmacist or nurse and will be identical in appearance, volume, and labeling.
-
Placebo
-
Used
-
Assignment
-
Parallel
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2026-07-19, 1405/04/28
-
Ethics committee reference number
-
IR.SBMU.RETECH.REC.1405.225
Health conditions studied
1
-
Description of health condition studied
-
Early postoperative sleep disturbance in patients undergoing major abdominal surgery
-
ICD-10 code
-
G47
-
ICD-10 code description
-
Sleep disorders
Primary outcomes
1
-
Description
-
The incidence of postoperative sleep disturbance on the first postoperative day. Postoperative sleep disturbance is defined as an Athens Insomnia Scale (AIS) score of 6 or higher or a Sleep Numerical Rating Scale (Sleep NRS) score of 6 or lower. Patients meeting at least one of these criteria will be considered to have postoperative sleep disturbance.
-
Timepoint
-
after the first and third postoperative nights.
-
Method of measurement
-
Measurement will be performed using the Athens Insomnia Scale and the Sleep Numerical Rating Scale.
Secondary outcomes
1
-
Description
-
Postoperative pain intensity at rest and during coughing or movement, measured using the Visual Analog Scale. A score of 0 indicates no pain, and a score of 10 indicates the worst imaginable pain.
-
Timepoint
-
On postoperative days 1 and 3, after the first and third postoperative nights.
-
Method of measurement
-
Postoperative pain intensity at rest and during coughing or movement, measured using the Visual Analog Scale. A score of 0 indicates no pain, and a score of 10 indicates the worst imaginable pain.
Intervention groups
1
-
Description
-
Intervention group: Following induction of general anesthesia, patients will receive an intravenous bolus of ketamine at 0.25 mg/kg body weight, followed by a continuous intravenous infusion of ketamine at 0.1 mg/kg/h until skin closure. Ketamine administration will be limited to the intraoperative period and will not be continued after surgery. Other anesthetic care and postoperative pain management will be provided according to the center’s standard protocol
-
Category
-
Prevention
2
-
Description
-
Control group: Following induction of general anesthesia, patients will receive an intravenous bolus of normal saline, followed by a continuous infusion of normal saline at an equivalent volume and rate until skin closure. Placebo administration will be limited to the intraoperative period and will not be continued after surgery. Other anesthetic care and postoperative pain management will be provided in accordance with the center’s standard protocols.
-
Category
-
Placebo
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Shahid Beheshti University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
2
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
No
-
Title of funding source
-
Anesthesiology Research Center, Taleghani Hospital
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
No - There is not a plan to make this available
-
Justification/reason for indecision/not sharing IPD
-
Deidentified individual participant data will not be shared because no formal data-sharing plan has been established, and access to study data will be restricted to authorized members of the research team to protect participant confidentiality.
-
Study Protocol
-
Undecided - It is not yet known if there will be a plan to make this available
-
Statistical Analysis Plan
-
Undecided - It is not yet known if there will be a plan to make this available
-
Informed Consent Form
-
Undecided - It is not yet known if there will be a plan to make this available
-
Clinical Study Report
-
Undecided - It is not yet known if there will be a plan to make this available
-
Analytic Code
-
Undecided - It is not yet known if there will be a plan to make this available
-
Data Dictionary
-
Undecided - It is not yet known if there will be a plan to make this available